PURPOSE: A quality improvement project was implemented to improve adherence to evidence-based antiemetic guidelines for malignant glioma patients treated with moderately emetic chemotherapy (MEC). Poorly controlled chemotherapy-induced nausea and vomiting (CINV) reduce cancer treatment efficacy and significantly impair cancer patients' quality of life (QOL). A review of Duke University Preston Robert Tisch Brain Tumor Center (PRTBTC)'s usual practice demonstrates a high incidence (45%) of CINV, despite premedication with short-acting 5-HT3-serotonin-receptor antagonists (5-HT3-RAs). National Comprehensive Cancer Network (NCCN)'s evidence-based guidelines recommend the combination of the long-acting 5-HT3-RA palonosetron (PAL) and dexamethasone (DEX) for the prevention of acute and delayed CINV with MEC. Low adherence (58%) to antiemetic guidelines may have explained our high CINV incidence. METHODS: One-sample binomial test, quasi-experimental design, evaluated a combination intervention that included a provider education session; implementation of risk-assessment tool with computerized, standardized antiemetic guideline order sets; and a monthly audit-feedback strategy. Post-implementation adherence to evidence-based antiemetic order sets and patient outcomes were measured and compared to baseline and historical data. Primary outcome was the guideline order set adherence rate. Secondary outcomes included nausea/vomiting rates and QOL. RESULTS: Adherence to ordering MEC guideline antiemetics increased significantly, from 58% to a sustained 90%, with associated improvement in nausea/vomiting. In acute and delayed phases, 75 and 84% of patients, respectively, did not experience CINV. There was no significant change in QOL. CONCLUSION: Combination intervention and audit-feedback strategy to translate evidence into oncology practice improved and sustained adherence to antiemetic guidelines. Adherence corresponded with effective nausea/vomiting control and preserved QOL in patients with malignant gliomas.
PURPOSE: A quality improvement project was implemented to improve adherence to evidence-based antiemetic guidelines for malignant gliomapatients treated with moderately emetic chemotherapy (MEC). Poorly controlled chemotherapy-induced nausea and vomiting (CINV) reduce cancer treatment efficacy and significantly impair cancerpatients' quality of life (QOL). A review of Duke University Preston Robert Tisch Brain Tumor Center (PRTBTC)'s usual practice demonstrates a high incidence (45%) of CINV, despite premedication with short-acting 5-HT3-serotonin-receptor antagonists (5-HT3-RAs). National Comprehensive Cancer Network (NCCN)'s evidence-based guidelines recommend the combination of the long-acting 5-HT3-RA palonosetron (PAL) and dexamethasone (DEX) for the prevention of acute and delayed CINV with MEC. Low adherence (58%) to antiemetic guidelines may have explained our high CINV incidence. METHODS: One-sample binomial test, quasi-experimental design, evaluated a combination intervention that included a provider education session; implementation of risk-assessment tool with computerized, standardized antiemetic guideline order sets; and a monthly audit-feedback strategy. Post-implementation adherence to evidence-based antiemetic order sets and patient outcomes were measured and compared to baseline and historical data. Primary outcome was the guideline order set adherence rate. Secondary outcomes included nausea/vomiting rates and QOL. RESULTS: Adherence to ordering MEC guideline antiemetics increased significantly, from 58% to a sustained 90%, with associated improvement in nausea/vomiting. In acute and delayed phases, 75 and 84% of patients, respectively, did not experience CINV. There was no significant change in QOL. CONCLUSION: Combination intervention and audit-feedback strategy to translate evidence into oncology practice improved and sustained adherence to antiemetic guidelines. Adherence corresponded with effective nausea/vomiting control and preserved QOL in patients with malignant gliomas.
Authors: Wilson C Mertens; Donald J Higby; David Brown; Regina Parisi; Janice Fitzgerald; Evan M Benjamin; Peter K Lindenauer Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Jørn Herrstedt; Jim M Koeller; Fausto Roila; Paul J Hesketh; David Warr; Cynthia Rittenberg; Mario Dicato Journal: Support Care Cancer Date: 2004-11-23 Impact factor: 3.603
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Pascale Dielenseger; Sussanne Börjeson; Cheryl Vidall; Annie Young; Patrick Jahn Journal: Support Care Cancer Date: 2019-02-19 Impact factor: 3.603
Authors: Mallika P Patel; Sarah Woodring; Dina M Randazzo; Henry S Friedman; Annick Desjardins; Patrick Healy; James E Herndon; Frances McSherry; Eric S Lipp; Elizabeth Miller; Katherine B Peters; Mary Lou Affronti Journal: Support Care Cancer Date: 2019-08-22 Impact factor: 3.603
Authors: Mary Lou Affronti; Sarah Woodring; Katherine B Peters; James E Herndon; Frances McSherry; Patrick N Healy; Annick Desjardins; James J Vredenburgh; Henry S Friedman Journal: Ther Clin Risk Manag Date: 2016-12-23 Impact factor: 2.423
Authors: Matti Aapro; Meinolf Karthaus; Lee Schwartzberg; Igor Bondarenko; Tomasz Sarosiek; Cristina Oprean; Servando Cardona-Huerta; Vincent Hansen; Giorgia Rossi; Giada Rizzi; Maria Elisa Borroni; Hope Rugo Journal: Support Care Cancer Date: 2016-11-24 Impact factor: 3.603